Overview

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Oryx GmbH & Co. KG